Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Participants in the initial Multicenter Study of Hydroxyurea in Sickle Cell Anemia interventional trial were followed, upon completion of that trial for up to 9 years, to determine the long-term effects of treatment. In this publication of the observational phase of the MSH trial, there is noted a 40% reduction in mortality for those who had received a year or more of the drug.

Reducing Mortality in Sickle Cell Disease with Hydroxyurea